Effect of adding vildagliptin to insulin in haemodialysed patients with type 2 diabetes: The VILDDIAL study, a randomized, multicentre, prospective study.

Marion MunchLaurent MeyerThierry HannedoucheKristian KunzFarideh AlenabiPatrice WiniszewskiPhilippe BaltzingerAgnès SmagalaAlexandre KleinFrançois DoreyDominique FleuryOdile Verier-MineBruno GuerciJoëlle CridligSophie BorotDidier DuclouxNicolas MeyerSamy HadjadjFrançois ChantrelLaurence Kessler

Published in: Diabetes, obesity & metabolism (2020)

In this study, vildagliptin added to insulin improved glycaemic control with an associated insulin-sparing effect in patients with type 2 diabetes undergoing haemodialysis and was well tolerated.

Keyphrases

type diabetes
glycemic control
clinical trial
metabolic syndrome
adipose tissue
chronic kidney disease
insulin resistance
skeletal muscle
end stage renal disease